NYCOMED GmbH Patent applications |
Patent application number | Title | Published |
20130231374 | Novel Process For The Preparation Of Roflumilast - A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight. | 09-05-2013 |
20130224299 | Novel Process For The Preparation Of Roflumilast - A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight. | 08-29-2013 |
20130143849 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES - Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children. | 06-06-2013 |
20130131123 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 μg of the roflumilast or salt thereof. | 05-23-2013 |
20130096152 | NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES - Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions. | 04-18-2013 |
20130095146 | CICLESONIDE CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION - An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided. | 04-18-2013 |
20130045974 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS - Compounds of the formula Ia***** | 02-21-2013 |
20130012544 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase. | 01-10-2013 |
20120294942 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST - The invention relates to novel processes for the preparation of high-purity roflumilast. | 11-22-2012 |
20120289474 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES - The compounds of Formula (1), | 11-15-2012 |
20120247982 | STABILIZED PHARMACEUTICAL PRODUCT - Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. | 10-04-2012 |
20120196867 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR - The claimed subject matter relates to pharmaceutical compositions comprising a PDE4 inhibitor and a PDE5 inhibitor and the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental. | 08-02-2012 |
20120149721 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES - The compounds of Formula (I), | 06-14-2012 |
20120142633 | METHYLPYRROLOPYRIDINECARBOXAMIDES - The compounds of Formula (I), | 06-07-2012 |
20120129817 | COMBINATION TREATMENT FOR DIABETES MELLITUS - The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1. | 05-24-2012 |
20120090606 | APPARATUS FOR THE AEROSOLIZATION OF LARGE VOLUMES OF DRY POWDER - The claimed subject matter relates to a device for dosing and aerosolization of aerosolizable material. The device comprises: a body with an aerosolization channel with a distal attachment portion connectable to a source of carrier gas which provides pressure pulses to the aerosolization channel; a proximal attachment portion for outputting aerosolized material and a reservoir for receiving aerosolizable material. The reservoir comprises walls and is connected in a gas-tight manner to the body and in fluid connection with the aerosolization channel. At least part of the walls of the device are self-exciting membranes that can be put into oscillation by the pressure pulses. | 04-19-2012 |
20120083512 | PHARMACEUTICAL PRODUCT FOR INJECTION - The claimed subject matter is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container and closure are made of material which essentially does not release zinc ions. | 04-05-2012 |
20110313005 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 12-22-2011 |
20110308975 | STABILIZED PHARMACEUTICAL PRODUCT - Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. | 12-22-2011 |
20110269750 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS - The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2. | 11-03-2011 |
20110257221 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS - Compounds of the formula Ia***** | 10-20-2011 |
20110257169 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS - Compounds of the formula Ia***** | 10-20-2011 |
20110251244 | Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-13-2011 |
20110218201 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS - The compounds of Formula (I), | 09-08-2011 |
20110171303 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT - Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described. | 07-14-2011 |
20110136803 | Triazolophthalazines - The compounds of formula (I) | 06-09-2011 |
20110108027 | FILTERING DEVICE, METHOD FOR FILTERING OF A FLUID, AND USE OF THE FILTERING DEVICE - A filtering device comprises a filtering means ( | 05-12-2011 |
20110092471 | USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS - The subject matter of this application relates to the combination of ciclesonide with an antihistamine. | 04-21-2011 |
20110086827 | COMBINATION MEDICAMENT - The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof. | 04-14-2011 |
20110064814 | STABLE PHARMACEUTICAL PRODUCTS - Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide. | 03-17-2011 |
20110060016 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Disclosed is a method of treatment of COPD by oral administration of roflumilast. | 03-10-2011 |
20110044938 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES - Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity. | 02-24-2011 |
20110021479 | PYRROLOPYRIMIDINECARBOXAMIDES - The compounds of Formula (I), | 01-27-2011 |
20100317650 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS - The compounds of formula (I) | 12-16-2010 |
20100286140 | TRIAZOLOPHTHALAZINES - The compounds of formula I | 11-11-2010 |
20100247585 | STABILIZED PHARMACEUTICAL PRODUCT - Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. | 09-30-2010 |
20100234382 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR - The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental. | 09-16-2010 |
20100190818 | Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives - The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical composition for use, e.g., in treatment of airway disorders. | 07-29-2010 |
20100179152 | Novel use for PDE5 inhibitors - The present invention is concerned with the use of PDE5 inhibitors in medicine. | 07-15-2010 |
20100179131 | Combination treatment for diabetes mellitus - The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1. | 07-15-2010 |
20100120757 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compounds of a certain formula 1, | 05-13-2010 |
20100120730 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS - The compounds of formula (I) | 05-13-2010 |
20100069392 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease - The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease. | 03-18-2010 |
20100035913 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors - The compounds of a certain formula (1), | 02-11-2010 |
20100034696 | Ciclesonide-containing sterile aqueous suspension - The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension. | 02-11-2010 |
20100022779 | Isotopically substituted proton pump inhibitors - The invention relates to compounds of formula 1 | 01-28-2010 |
20090297473 | Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors - Compounds of a certain formula 1, | 12-03-2009 |
20090270378 | NOVEL TETRAHYDROPYRIDOTHIOPHENES - Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity. | 10-29-2009 |
20090263353 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles - Compounds of a certain formula I, | 10-22-2009 |
20090239895 | Novel 3-thia-10-aza-phenanthrene derivatives - The compounds of formula I | 09-24-2009 |
20090215836 | Roflumilast for the Treatment of Pulmonary Hypertension - The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension. | 08-27-2009 |
20090211577 | Device for Dosing and Dry Nebulization - The invention relates to a device | 08-27-2009 |
20090209591 | Pharmaceutical product for injection - The present invention is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container and closure are made of material which essentially does not release zinc ions. | 08-20-2009 |
20090208571 | Dosage form containing pantoprazole as active ingredient - Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. | 08-20-2009 |
20090171096 | Novel process for the preparation of roflumilast - The invention relates to novel processes for the preparation of high-purity roflumilast. | 07-02-2009 |
20090170892 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors - The compounds of formula I | 07-02-2009 |
20090170125 | Cellular assay method for identifying pkc-0 inhibitors - The invention relates to a method for investigating the modulating effect of a test substance on a PKCθ-dependent signal transduction pathway or for finding a PKCθ modulator in a human or animal cell, including the steps
| 07-02-2009 |
20090134211 | Method - The present invention relates to a method for the provision of clinical trial products in the context of clinical trials. | 05-28-2009 |
20090131448 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors - The compounds of a certain formula (1), | 05-21-2009 |
20090131399 | Imidazopyridine Derivatives Useful as iNOS Inhibitors - The compounds of formula (I) | 05-21-2009 |
20090117074 | Sulfonylpyrroles as Histone Deacetylase Inhibitors - The invention relates to compounds of formula (I) | 05-07-2009 |
20090030065 | Use of Pde1c and Inhibitors Thereof - The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases. | 01-29-2009 |
20090020442 | Method for the Provision of Clinical Trial Products - The present invention relates to a method for the provision of clinical trial products and packaging of clinical trial products using RFID units in the context of clinical trials. | 01-22-2009 |
20090000615 | Device for Dosing and Dry Nebulization - The invention relates to a device ( | 01-01-2009 |
20080319067 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors - The compounds of formula I | 12-25-2008 |
20080312225 | Triazolophthalazines - The compounds of formula (I) | 12-18-2008 |
20080280958 | Topically applicable pharmaceutical preparation - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 11-13-2008 |
20080280855 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles - The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. | 11-13-2008 |
20080260749 | Novel Tetrahydropyridothiophenes - Compounds of a certain formula (I) | 10-23-2008 |
20080257339 | Aerosol Container - The present invention relates to an aerosol container with an RFID unit applied to a spacer connected to the base of the aerosol container. | 10-23-2008 |
20080255209 | Combination of a NSAID and a PDE-4 inhibitor - The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof. | 10-16-2008 |
20080226712 | Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles - The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. | 09-18-2008 |
20080221111 | Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative - The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases. | 09-11-2008 |
20080214536 | Amido-Substituted 6-Phenylphenanthridines - Compounds of a certain formula (I) | 09-04-2008 |